Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market - Global Outlook and Forecast 2022-2028
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
This report contains market size and forecasts of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Global, including the following market information:
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market was valued at 7854.6 million in 2021 and is projected to reach US$ 11030 million by 2028, at a CAGR of 5.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation and Bayer AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment Percentages, by Type, 2021 (%)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment Percentages, by Application, 2021 (%)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
This report contains market size and forecasts of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Global, including the following market information:
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market was valued at 7854.6 million in 2021 and is projected to reach US$ 11030 million by 2028, at a CAGR of 5.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation and Bayer AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment Percentages, by Type, 2021 (%)
- Oral Therapy
- Injectable Therapy
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment Percentages, by Application, 2021 (%)
- Hospitals & Clinics
- Home Settings
- Ambulatory Surgical Centers (ASCs)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Astellas Inc.
- Johnson & Johnson
- Sanofi S.A
- Dendreon Corporation
- Bayer AG
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS OVERALL MARKET SIZE
2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size: 2021 VS 2028
2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players in Global Market
3.2 Top Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies Ranked by Revenue
3.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Markets, 2021 & 2028
4.1.2 Oral Therapy
4.1.3 Injectable Therapy
4.2 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2021 & 2028
5.1.2 Hospitals & Clinics
5.1.3 Home Settings
5.1.4 Ambulatory Surgical Centers (ASCs)
5.2 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.3.2 US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.3.3 Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.3.4 Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.4.2 Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.3 France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.4 U.K. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.5 Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.6 Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.8 Benelux Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.5.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5.3 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5.4 South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5.6 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.6.2 Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.6.3 Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.7.2 Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.7.3 Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.7.5 UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Astellas Inc.
7.1.1 Astellas Inc. Corporate Summary
7.1.2 Astellas Inc. Business Overview
7.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.1.4 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.1.5 Astellas Inc. Key News
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Corporate Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.2.4 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.2.5 Johnson & Johnson Key News
7.3 Sanofi S.A
7.3.1 Sanofi S.A Corporate Summary
7.3.2 Sanofi S.A Business Overview
7.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.3.5 Sanofi S.A Key News
7.4 Dendreon Corporation
7.4.1 Dendreon Corporation Corporate Summary
7.4.2 Dendreon Corporation Business Overview
7.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.4.4 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Dendreon Corporation Key News
7.5 Bayer AG
7.5.1 Bayer AG Corporate Summary
7.5.2 Bayer AG Business Overview
7.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.5.4 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.5.5 Bayer AG Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS OVERALL MARKET SIZE
2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size: 2021 VS 2028
2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players in Global Market
3.2 Top Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies Ranked by Revenue
3.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Markets, 2021 & 2028
4.1.2 Oral Therapy
4.1.3 Injectable Therapy
4.2 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2021 & 2028
5.1.2 Hospitals & Clinics
5.1.3 Home Settings
5.1.4 Ambulatory Surgical Centers (ASCs)
5.2 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.3.2 US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.3.3 Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.3.4 Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.4.2 Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.3 France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.4 U.K. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.5 Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.6 Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.4.8 Benelux Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.5.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5.3 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5.4 South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.5.6 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.6.2 Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.6.3 Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028
6.7.2 Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.7.3 Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
6.7.5 UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Astellas Inc.
7.1.1 Astellas Inc. Corporate Summary
7.1.2 Astellas Inc. Business Overview
7.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.1.4 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.1.5 Astellas Inc. Key News
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Corporate Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.2.4 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.2.5 Johnson & Johnson Key News
7.3 Sanofi S.A
7.3.1 Sanofi S.A Corporate Summary
7.3.2 Sanofi S.A Business Overview
7.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.3.5 Sanofi S.A Key News
7.4 Dendreon Corporation
7.4.1 Dendreon Corporation Corporate Summary
7.4.2 Dendreon Corporation Business Overview
7.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.4.4 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Dendreon Corporation Key News
7.5 Bayer AG
7.5.1 Bayer AG Corporate Summary
7.5.2 Bayer AG Business Overview
7.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
7.5.4 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
7.5.5 Bayer AG Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Opportunities & Trends in Global Market
Table 2. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers in Global Market
Table 3. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints in Global Market
Table 4. Key Players of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Global Market
Table 5. Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Type
Table 9. List of Global Tier 1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Astellas Inc. Corporate Summary
Table 31. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 32. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Johnson & Johnson Corporate Summary
Table 34. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 35. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Sanofi S.A Corporate Summary
Table 37. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 38. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Dendreon Corporation Corporate Summary
Table 40. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 41. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Bayer AG Corporate Summary
Table 43. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 44. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
Table 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Opportunities & Trends in Global Market
Table 2. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers in Global Market
Table 3. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints in Global Market
Table 4. Key Players of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Global Market
Table 5. Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Type
Table 9. List of Global Tier 1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Astellas Inc. Corporate Summary
Table 31. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 32. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Johnson & Johnson Corporate Summary
Table 34. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 35. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Sanofi S.A Corporate Summary
Table 37. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 38. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Dendreon Corporation Corporate Summary
Table 40. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 41. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Bayer AG Corporate Summary
Table 43. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings
Table 44. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Type in 2021
Figure 2. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Application in 2021
Figure 3. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in 2021
Figure 8. By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Type in 2021
Figure 2. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Application in 2021
Figure 3. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in 2021
Figure 8. By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
